1,945,576 Shares CLINICAL DATA, INC. Common Stock UNDERWRITING AGREEMENT
Exhibit 1.1
1,945,576 Shares
CLINICAL DATA, INC.
Common Stock
June 9, 2010
BMO CAPITAL MARKETS CORP.
As Representative of the Several Underwriters
0 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
As Representative of the Several Underwriters
0 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Clinical Data, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms
and conditions stated herein, to issue and sell an aggregate of 1,945,576 shares (the “Firm
Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), to the
several underwriters named in Schedule I (collectively, the “Underwriters”), for whom BMO
Capital Markets Corp. is acting as representative (the “Representative”). The Company has also
granted to the several Underwriters an option to purchase up to 291,836 additional shares of
Common Stock on the terms and for the purposes set forth in Section 1 hereof (the “Option Shares”).
The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively
called the “Securities.”
The public offering price per share at which the Securities are initially offered and the
purchase price per share for the Securities to be paid by Underwriters shall be agreed upon by the
Company and the Representative, acting on behalf of the several Underwriters. The offering of the
Securities shall be governed by this Agreement.
The Company confirms as follows its agreement with the Representative and the several other
Underwriters:
1. Agreement to Sell and Purchase.
(a) Firm Shares. On the basis of the representations, warranties and agreements of the
Company herein contained and subject to all the terms and conditions of this Agreement, the Company
agrees to sell to the several Underwriters and each of the several Underwriters, severally and not
jointly, agrees to purchase from the Company, at the purchase price per share to be agreed upon by
the Company and the Representative, the number of Firm Shares set forth opposite the name of such
Underwriter in Schedule I, plus such additional number of Firm Shares which such
Underwriter may become obligated to purchase pursuant to Section 8 hereof.
(b) Option Shares. On the basis of the representations, warranties and agreements of the
Company herein contained and subject to all the terms and conditions of this Agreement, the Company
hereby grants to the several Underwriters an option to purchase all or any portion of the Option
Shares at the same purchase price as the Firm Shares, for use solely in covering any over
allotments made by the Underwriters in the sale and distribution of the Firm Shares. The option
granted hereunder may be exercised in whole or in part at any time and from time to time within 30
days after the effective date of this Agreement upon notice (confirmed in writing) by the
Representative to the Company setting forth the aggregate number of Option Shares as to which the
several Underwriters are exercising the option, the names and denominations in which the
certificates for the Option Shares are to be registered and the date and time, as determined by the
Representative, when the Option Shares are to be delivered. The number of Option Shares to be
purchased by each Underwriter shall be the same percentage of the total number of Option Shares to
be purchased by the several Underwriters as the number of Firm Shares to be purchased by such
Underwriter is of the total number of Firm Shares to be purchased by the several Underwriters, as
adjusted by the Representative in such manner as the Representative deems advisable to avoid
fractional shares. No Option Shares shall be sold and delivered unless the Firm Shares previously
have been, or simultaneously are, sold and delivered.
2. Delivery and Payment.
(a) Closing. Delivery of the Firm Shares shall be made to the Representative through the
facilities of the Depository Trust Company (“DTC”) for the respective accounts of the Underwriters
against payment of the purchase price by wire transfer of immediately available funds to the order
of the Company at the offices of Xxxxxx LLP, 000 Xxxxxxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx (or such
other place as may be agreed upon among the Representative and the Company). Such payment shall be
made at 10:00 a.m., New York time, on the third business day (the fourth business day, should the
offering be priced after 4:00 p.m., New York time) after the date on which the first bona fide
offering of the Securities to the public is made by the Underwriters or at such time on such other
date, not later than ten business days after such date, as may be agreed upon by the Company and
the Representative (such date is hereinafter referred to as the “Closing Date”).
Delivery of the Option Shares shall be made to the Representative through the facilities of
DTC for the respective accounts of the Underwriters against payment of the purchase price by wire
transfer of immediately available funds to the order of the Company on such date and at such time,
as determined by the Representative (the “Second Closing Date”), provided, however, that the Second
Closing Date shall not be earlier than the Closing Date nor earlier than the second business day
after the date on which the option shall have been exercised.
(b) Electronic Transfer. Electronic transfer of Securities shall be made at the time of
purchase in such names and in such denominations as the Representative shall specify.
(c) Tax Stamps. The cost of original issue tax stamps, if any, in connection with the
issuance and delivery of the Securities by the Company to the respective Underwriters shall be
borne by the Company. The Company shall pay and hold each Underwriter and any subsequent holder of
the Securities harmless from any and all liabilities with respect to or resulting from any failure
or delay in paying Federal and state stamp and other transfer taxes, if
2
any, which may be payable or determined to be payable in connection with the original issuance
or sale to such Underwriter of the Securities.
3. Representations and Warranties of the Company. The Company represents and warrants
to, and covenants with, each Underwriter as follows:
(a) The Company has prepared and filed with the Securities and Exchange Commission (the
“Commission”) a registration statement on Form S-3 (File No. 333-143883) under the Securities Act
of 1933, as amended (the “Securities Act” or “Act”) and the rules and regulations (the “Rules and
Regulations”) of the Commission thereunder, and such amendments to such registration statement as
may have been required to the date of this Agreement. Such registration statement has been declared
effective by the Commission. Such registration statement, at any given time, including amendments
thereto to such time, the exhibits and any schedules thereto at such time, the documents
incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act at such
time and the documents and information otherwise deemed to be a part thereof or included therein by
Rule 430B under the Securities Act (the “Rule 430B Information”) or otherwise pursuant to the
Rules and Regulations at such time, is herein called the “Registration Statement.” The
Registration Statement at the time it originally became effective is herein called the “Original
Registration Statement.” Any registration statement filed by the Company pursuant to Rule 462(b)
under the Securities Act is called the “Rule 462 Registration Statement” and, from and after the
date and time of filing of the Rule 462 Registration Statement, the term “Registration Statement”
shall include the Rule 462 Registration Statement.
The prospectus in the form in which it appeared in the Original Registration Statement is
herein called the “Base Prospectus.” Each preliminary prospectus supplement to the Base Prospectus
(including the Base Prospectus as so supplemented), that describes the Securities and the offering
thereof, that omitted the Rule 430B Information and that was used prior to the filing of the final
prospectus supplement referred to in the following sentence is herein called a “Preliminary
Prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and
file with the Commission a final prospectus supplement to the Base Prospectus relating to the
Securities and the offering thereof in accordance with the provisions Rule 430B and Rule 424(b) of
the Rules and Regulations. Such final supplemental form of prospectus (including the Base
Prospectus as so supplemented), in the form filed with the Commission pursuant to Rule 424(b) is
herein called the “Prospectus.” Any reference herein to the Base Prospectus, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to include the documents incorporated by
reference therein pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such
prospectus.
For purposes of this Agreement, all references to the Registration Statement, the Rule 462(b)
Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Prospectus or any
amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the
Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“XXXXX”). All
references in this Agreement to financial statements and schedules and other information which is
“described,” “contained,” “included” or “stated” in the Registration Statement, the Base
Prospectus, any Preliminary Prospectus or the Prospectus (or other references of like import) shall
be deemed to mean and include all such financial
3
statements and schedules and other information which is incorporated by reference in or
otherwise deemed by the Rules and Regulations to be a part of or included in the Registration
Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be;
and all references in this Agreement to amendments or supplements to the Registration Statement,
the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to mean and
include the subsequent filing of any document under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) and which is deemed to be incorporated therein by reference therein or
otherwise deemed by the Rules and Regulations to be a part thereof.
(b) The General Disclosure Package (as defined below) at the Applicable Time (as defined
below) complied in all material respects with the requirements of the Securities Act and the Rules
and Regulations and did not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The preceding sentence does
not apply to statements in or omissions from the General Disclosure Package based upon and in
conformity with written information furnished to the Company by any Underwriter through the
Representative specifically for use therein. For all purposes of this Agreement, the amounts of
the selling concession and reallowance set forth in the Prospectus constitute the only information
relating to any Underwriter furnished in writing to the Company by the Representative specifically
for inclusion in the Preliminary Prospectus, the Registration Statement or the Prospectus.
(c) The Original Registration Statement was initially declared effective by the Commission
under the Securities Act on June 28, 2007. The Company has complied, to the Commission’s
satisfaction, with all requests of the Commission for additional or supplemental information. No
stop order suspending the effectiveness of the Registration Statement is in effect and no
proceedings for such purpose have been instituted or are pending or, to the best knowledge of the
Company, are contemplated or threatened by the Commission.
(d) Each part of the Registration Statement, any Rule 462 Registration Statement and any
post-effective amendment thereto, at the time such part became effective (including each deemed
effective date with respect to the Underwriters pursuant to Rule 430B or otherwise under the
Securities Act), at all other subsequent times until the expiration of the Prospectus Delivery
Period (as defined below), and at the Closing Date and the Second Closing Date (as hereinafter
defined), as the case may be, and the Prospectus, at the time of filing or the time of first use
within the meaning of the Rules and Regulations, at all subsequent times until expiration of the
Prospectus Delivery Period, and at the Closing Date and the Second Closing Date, as the case may
be, complied and will comply in all material respects with the applicable requirements and
provisions of the Securities Act, the Rules and Regulations and the Exchange Act and did not and
will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. The Prospectus,
as amended or supplemented, as of its date, or the time of first use within the meaning of the
Rules and Regulations, at all subsequent times until the expiration of the Prospectus Delivery
Period, and at the Closing Date and the Second Closing Date, as the case may be, did not and will
not contain any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The representations and warranties set forth in the
4
two immediately preceding sentences do not apply to statements in or omissions from the
Registration Statement, any Rule 462 Registration Statement, or any post-effective amendment
thereto, or the Prospectus, made in reliance upon and in conformity with written information
relating to an Underwriter furnished to the Company by any Underwriter through the Representative
specifically for use therein.
(e) Neither (A) any Issuer General Use Free Writing Prospectus(es) issued at or prior to the
Applicable Time and set forth on Schedule III, the information set forth on Schedule
II and the Statutory Prospectus at the Applicable Time, all considered together (collectively,
the “General Disclosure Package”), nor (B) any individual Issuer Limited Use Free Writing
Prospectus, when considered together with the General Disclosure Package, includes or included as
of the Applicable Time any untrue statement of a material fact or omit or omitted as of the
Applicable Time to state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. The preceding sentence
does not apply to statements in or omissions from any Statutory Prospectus or any Issuer Free
Writing Prospectus based upon and in conformity with written information furnished to the Company
by any Underwriter through the Representative specifically for use therein. As used in this
paragraph and elsewhere in this Agreement:
(1) “Applicable Time” means 9:00 a.m. (New York time) on the date of this
Agreement.
(2) “Statutory Prospectus” means the Base Prospectus, as amended and supplemented
immediately prior to the Applicable Time, including any document incorporated by reference
therein and any prospectus supplement deemed to be a part thereof. For purposes of this
definition, Rule 430B Information contained in a form of prospectus that is deemed
retroactively to be a part of the Registration Statement shall be considered to be included
in the Statutory Prospectus as of the actual time that form of prospectus is filed with the
Commission pursuant to Rule 424(b) under the Securities Act.
(3) “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as
defined in Rule 433 under the Securities Act, relating to the Securities that (A) is
required to be filed with the Commission by the Company, or (B) is exempt from filing
pursuant to Rule 433(d)(5)(i) under the Securities Act because it contains a description of
the Securities or of the offering that does not reflect the final terms, or is a “bona fide
electronic roadshow,” as defined in Rule 433 of the Rules and Regulations, in each case in
the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities
Act.
(4) “Issuer General Use Free Writing Prospectus” means any Issuer Free Writing
Prospectus that is intended for general distribution to prospective investors, as evidenced
by its being specified in Schedule III hereto.
(5) “Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing
Prospectus that is not an Issuer General Use Free Writing Prospectus.
5
(f) (A) Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times
through the Prospectus Delivery Period or until any earlier date that the Company notified or
notifies the Underwriters as described in Section 4(c), did not, does not and will not include any
information that conflicted, conflicts or will conflict with the information contained in the
Registration Statement, any Statutory Prospectus or the Prospectus. The foregoing sentence does
not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in
conformity with written information furnished in writing to the Company by any Underwriter through
the Representative specifically for use therein.
(B)(1) At the earliest time after the filing of the Registration Statement that the Company or
another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the
Securities Act) of the Securities and (2) at the date hereof, the Company was not and is not an
“ineligible issuer,” as defined in Rule 405 under the Securities Act, in the preceding three years
not having been convicted of a felony or misdemeanor or having been made the subject of a judicial
or administrative decree or order as described in Rule 405 (without taking account of any
determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be
considered an ineligible issuer), nor an “excluded issuer” as defined in Rule 164 under the
Securities Act.
(C) Each Issuer Free Writing Prospectus satisfied, as of its issue date and at all subsequent
times through the Prospectus Delivery Period, all other conditions to use thereof as set forth in
Rules 164 and 433 under the Securities Act.
(g) The consolidated financial statements of the Company and its subsidiaries, together with
the related notes, set forth or incorporated by reference, in the Registration Statement, the
General Disclosure Package and the Prospectus comply in all material respects with the requirements
of the Securities Act and fairly present the financial condition of the Company and its
consolidated subsidiaries as of the dates indicated and the results of operations and changes in
cash flows for the periods therein specified in conformity with generally accepted accounting
principles in the United States consistently applied throughout the periods involved; and the
supporting schedules included in the Registration Statement, the General Disclosure Package and the
Prospectus have been derived from the accounting records of the Company and present fairly the
information required to be stated therein. No other schedules or financial statements are required
to be included in the Registration Statement, the General Disclosure Package or the Prospectus. To
the Company’s knowledge, Deloitte & Touche LLP (the “Accountants”), which has expressed its opinion
with respect to the financial statements filed as a part of the Registration Statement and included
in the Registration Statement, the General Disclosure Package and the Prospectus, is (x) an
independent public accounting firm within the meaning of the Securities Act and the Rules and
Regulations, (y) a registered public accounting firm (as defined in Section 2(a)(12) of the
Xxxxxxxx-Xxxxx Act of 2002 (the “Xxxxxxxx-Xxxxx Act”)) and (z) in the performance of its work for
the Company, not in violation of the auditor independence requirements of the Xxxxxxxx-Xxxxx Act.
Except as described in the General Disclosure Package and the Prospectus, there are no material
off-balance sheet transactions, arrangements, obligations (including contingent obligations), or
any other relationships with unconsolidated entities or other persons, that may have a material
current or, to the Company’s knowledge, future effect on the Company’s financial condition, changes
in financial condition, results of operations, liquidity, capital expenditures, capital resources
or significant components
6
of revenue or expenses. All non-GAAP financial information included in the Registration
Statement, the General Disclosure Package and the Prospectus complies with the requirements of
Regulation G and Item 10 of Regulation S-K under the Act.
(h) Each of the Company and its subsidiaries has been duly organized and is validly existing
as a corporation in good standing under the laws of its jurisdiction of incorporation. Each of the
Company and its subsidiaries has full corporate power and authority to own its properties and
conduct its business as currently being conducted and as described in the Registration Statement,
the General Disclosure Package and the Prospectus, and is duly qualified to do business as a
foreign corporation in good standing in each jurisdiction in which it owns or leases real property
or in which the conduct of its business makes such qualification necessary and in which the failure
to so qualify might result in a material adverse change in the general affairs, condition
(financial or otherwise), business, prospects, property, operations or results of operations of the
Company and its subsidiaries, taken as a whole (“Material Adverse Change”). All of the issued
shares of capital stock of each subsidiary of the Company have been duly and validly authorized and
issued, are fully paid and non-assessable and are owned directly by the Company, free and clear of
all liens, encumbrances, equities or claims.
(i) Except as contemplated in the General Disclosure Package and the Prospectus, subsequent to
the respective dates as of which information is given in the General Disclosure Package, (a)
neither the Company nor any of its subsidiaries has incurred any material liabilities or
obligations, direct or contingent, or entered into any material transactions, or declared or paid
any dividends or made any distribution of any kind with respect to its capital stock; and (b) there
has not been any change in the capital stock (other than a change in the number of outstanding
shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or
warrants), or any material change in the short term or long term debt, or any issuance of options,
warrants, convertible securities or other rights to purchase the capital stock, of the Company or
any of its subsidiaries (other than issuances of options under the Company’s existing stock option
plans), or any Material Adverse Change or any development that could reasonably be expected to
result in a Material Adverse Change.
(j) Except as set forth in the General Disclosure Package and the Prospectus, there is not
pending or, to the knowledge of the Company, threatened or contemplated, any action, suit or
proceeding to which the Company or any of its subsidiaries is a party or of which any property or
assets of the Company or any of its subsidiaries is the subject before or by any court or
governmental agency, authority or body, or any arbitrator, which, individually or in the aggregate,
could reasonably be expected to result in any Material Adverse Change. There are no current or
pending legal, governmental or regulatory actions, suits or proceedings that are required to be
described in the Registration Statement, the General Disclosure Package and the Prospectus that
have not been so described.
(k) There are no statutes, regulations, contracts or documents that are required to be
described in the Registration Statement, the General Disclosure Package and the Prospectus or to be
filed as exhibits to the Registration Statement by the Act or by the Rules and Regulations that
have not been so described or filed.
7
(l) This Agreement has been duly authorized, executed and delivered by the Company, and
constitutes a valid, legal and binding obligation of the Company, enforceable in accordance with
its terms, except as rights to indemnity hereunder may be limited by federal or state securities
laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or
similar laws affecting the rights of creditors generally and subject to general principles of
equity. The execution, delivery and performance of this Agreement and the consummation of the
transactions herein contemplated will not (A) conflict with or result in a breach or violation of
any of the terms or provisions of, or constitute a default under, or result in the creation or
imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of
its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which the Company or any of its subsidiaries are a party or by which the
Company or any of its subsidiaries are bound or to which any of the property or assets of the
Company or any of its subsidiaries is subject, except for any such conflict, breach violation,
default or imposition of a lien, charge or encumbrance that would not reasonably be expected to
result in a Material Adverse Change, (B) result in any violation of the provisions of the charter
or by-laws of the Company or any of its subsidiaries or (C) result in the violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental
agency or regulatory authority, except for any such violation that would not reasonably be expected
to result in a Material Adverse Change. No consent, approval, authorization or order of, or filing
with, any court or governmental agency or body is required for the execution, delivery and
performance of this Agreement or for the consummation of the transactions contemplated hereby,
including the issuance or sale of the Securities by the Company, except (i) such as may be required
under the Act, the rules of the Financial Industry Regulatory Authority (“FINRA”) or state
securities or blue sky laws or (ii) for any consent, approval, authorization, order or filing the
failure of which to make or obtain would not reasonably be expected to result in a Material Adverse
Change; and the Company has full power and authority to enter into this Agreement and to consummate
the transactions contemplated hereby including the authorization, issuance and sale of the
Securities as contemplated by this Agreement.
(m) All of the issued and outstanding shares of capital stock of the Company, including the
outstanding shares of Common Stock, are duly authorized and validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, were not
issued in violation of or subject to any preemptive rights or other rights to subscribe for or
purchase securities that have not been waived in writing (a copy of which has been delivered to
counsel to the Underwriters); the Securities which may be sold hereunder by the Company have been
duly authorized and, when issued, delivered and paid for in accordance with the terms of this
Agreement, will have been validly issued and will be fully paid and nonassessable, and the holders
thereof will not be subject to personal liability solely by reason of being such holders; and the
capital stock of the Company, including the Common Stock, conforms to the description thereof in
the Registration Statement, the General Disclosure Package and the Prospectus. Except as otherwise
described in the Registration Statement, the General Disclosure Package and the Prospectus, there
are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon
the voting or transfer of, any shares of Common Stock pursuant to the Company’s charter, by laws or
any agreement or other instrument to which the Company is a party or by which the Company is bound,
other than options to purchase common stock under the Company’s existing stock option plans.
Except as described in the Registration Statement, in
8
the General Disclosure Package and in the Prospectus, neither the filing of the Registration
Statement nor the offering or sale of the Securities as contemplated by this Agreement gives rise
to any rights for or relating to the registration of any shares of Common Stock or other securities
of the Company that have not been fully complied with or previously waived. All of the issued and
outstanding shares of capital stock of each of the Company’s subsidiaries have been duly and
validly authorized and issued and are fully paid and nonassessable, and, except as otherwise
described in the Registration Statement, in the General Disclosure Package and in the Prospectus,
the Company owns of record and beneficially, free and clear of any security interests, claims,
liens, proxies, equities or other encumbrances, all of the issued and outstanding shares of such
stock. Except as described or contemplated in the Registration Statement, the General Disclosure
Package and the Prospectus, there are no options, warrants, agreements, contracts or other rights
in existence to purchase or acquire from the Company any shares of the capital stock of the Company
or any subsidiary of the Company (other than issuances of options under the Company’s existing
stock option plans). The Company has an authorized and outstanding capitalization as set forth in
the Registration Statement, the General Disclosure Package and the Prospectus. The Common Stock
(including the Securities) conforms in all material respects to the description thereof contained
in the General Disclosure Package and the Prospectus. The description of the Company’s stock
option, stock bonus and other stock plans or arrangements, and the options or other rights granted
thereunder, set forth in the General Disclosure Package and the Prospectus accurately and fairly
presents the information required to be shown with respect to such plans, arrangements, options and
rights. Except as set forth in the General Disclosure Package, the Company is not a participant in
any joint venture, partnership or similar arrangement.
(n) The Company and each of its subsidiaries holds, and is operating in compliance in all
material respects with, all franchises, grants, authorizations, licenses, permits, easements,
consents, certificates and orders of any Governmental Authority or self-regulatory body required
for the conduct of its business, and all such franchises, grants, authorizations, licenses,
permits, easements, consents, certifications and orders are valid and in full force and effect; and
neither the Company nor any of its subsidiaries has received notice of any revocation or
modification of any such franchise, grant, authorization, license, permit, easement, consent,
certification or order or has reason to believe that any such franchise, grant, authorization,
license, permit, easement, consent, certification or order will not be renewed in the ordinary
course; and the Company and each of its subsidiaries is in compliance in all material respects with
all applicable federal, state, local and foreign laws, regulations, orders and decrees.
(o) The Company and its subsidiaries have good and marketable title to all property (whether
real or personal) described in the Registration Statement, the General Disclosure Package and the
Prospectus as being owned by them, in each case free and clear of all liens, claims, security
interests, other encumbrances or defects except as described in the Registration Statement, the
General Disclosure Package and the Prospectus, and except those that could not, individually or in
the aggregate, reasonably be expected to result in a Material Adverse Change. The property held
under lease by the Company and its subsidiaries is held by them under valid, subsisting and
enforceable leases with only such exceptions with respect to any particular lease as do not
interfere in any material respect with the conduct of the business of the Company or and its
subsidiaries.
9
(p) The Company and its subsidiaries own, possess, or can acquire on reasonable terms, all
Intellectual Property necessary for the conduct of their business as now conducted or as described
in the Registration Statement, the General Disclosure Package and the Prospectus to be conducted,
except as such failure to own, possess, or acquire such rights would not result in a Material
Adverse Change. Except as set forth in the Registration Statement, the General Disclosure Package
and the Prospectus, (A) to the knowledge of the Company, there is no infringement, misappropriation
or violation by third parties of any such Intellectual Property, except as such infringement,
misappropriation or violation would not result in a Material Adverse Change; (B) there is no
pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others
challenging the Company’s or its subsidiaries’ rights in or to any such Intellectual Property, and
the Company is unaware of any facts which would form a reasonable basis for any such claim; (C) the
Intellectual Property owned by the Company and its subsidiaries and to the knowledge of the
Company, the Intellectual Property licensed to the Company and its subsidiaries have not been
adjudged invalid or unenforceable, in whole or in part, and there is no pending or threatened
action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis
for any such claim; (D) there is no pending or threatened action, suit, proceeding or claim by
others that the Company or any of its subsidiaries infringe, misappropriate or otherwise violate
any Intellectual Property or other proprietary rights of others, neither the Company nor any of its
subsidiaries has received any written notice of such claim and the Company is unaware of any other
fact which would form a reasonable basis for any such claim; and (E) to the Company’s knowledge, no
employee of the Company or any of its subsidiaries is in or has ever been in violation of any term
of any employment contract, patent disclosure agreement, invention assignment agreement,
non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive
covenant to or with a former employer where the basis of such violation relates to such employee’s
employment with the Company or any of its subsidiaries or actions undertaken by the employee while
employed with the Company or any of its subsidiaries, except as such violation would not result in
a Material Adverse Change. “Intellectual Property” shall mean all patents, patent applications,
trade and service marks, trade and service xxxx registrations, trade names, copyrights, licenses,
inventions, trade secrets, technology, know-how and other intellectual property.
(q) Neither the Company nor any of its subsidiaries are (A) in violation of their charter or
by laws; (B) in breach of or otherwise in default, and no event has occurred which, with notice or
lapse of time or both, would constitute such a default in the performance or observance of any
term, covenant, obligation, agreement or condition contained in any bond, debenture, note,
indenture, loan agreement, mortgage, deed of trust or any other contract, lease or other instrument
to which it is subject or by which it may be bound, or to which any of the material property or
assets of the Company or any of its subsidiaries are subject; or (C) in violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory authority, except in the case of (B) and (C) above, as could not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Change.
(r) The Company and its subsidiaries have timely filed all federal, state, local and foreign
income and franchise tax returns required to be filed and are not in default in the payment of any
material taxes which were payable pursuant to said returns or any assessments with respect thereto,
other than any which the Company or any of its subsidiaries are contesting
10
in good faith. There is no pending dispute with any taxing authority relating to any of such
returns and the Company has no knowledge of any proposed liability for any tax to be imposed upon
the properties or assets of the Company or any of its subsidiaries for which there is not an
adequate reserve reflected in the Company’s financial statements included in the Registration
Statement, the General Disclosure Package and the Prospectus.
(s) Other than the subsidiaries of the Company listed in Exhibit 21 to the Company’s Annual
Report on Form 10-K for the fiscal year ended March 31, 2009, the Company, directly or indirectly,
owns no capital stock or other equity or ownership or proprietary interest in any corporation,
partnership, association, trust or other entity.
(t) The Company has not distributed and will not distribute any prospectus or other offering
material in connection with the offering and sale of the Securities other than the General
Disclosure Package or the Prospectus or other materials permitted by the Securities Act to be
distributed by the Company; provided, however, that, except as set forth on Schedule III,
the Company has not made and will not make any offer relating to the Securities that would
constitute a “free writing prospectus” as defined in Rule 405 under the Securities Act, except in
accordance with the provisions of Section 4(g) of this Agreement.
(u) The Common Stock of the Company is registered pursuant to Section 12(b) of the Exchange
Act and is listed on The NASDAQ Global Market (“NASDAQ”) under the ticker symbol “CLDA.” The
Company has taken no action designed to, or likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act or delisting the Common Stock from NASDAQ
nor has the Company received any notice that it is not in compliance with the listing or
maintenance requirements of NASDAQ. The Company believes that it is, and has no reason to believe
that it will not in the foreseeable future continue to be, in material compliance with all such
listing and maintenance requirements. Except as described in the Registration Statement, the
General Disclosure Package or the Prospectus, there are no affiliations among the Company’s
directors and officers and members of the FINRA. A Registration Statement relating to the Common
Stock on Form 8-A or other applicable form under the Exchange Act has become effective.
(v) To enable the Underwriters to rely on Rule 5110(b)(7)(C)(i) of FINRA, the Company
represents that, as of the date of this Agreement, the Company (i) has a non-affiliate, public
common equity float of at least $150 million or a non-affiliate, public common equity float of at
least $100 million and annual trading volume of at least three million shares and (ii) has been
subject to the Exchange Act reporting requirements for a period of at least 36 months.
(w) The Company maintains a system of internal accounting controls sufficient to provide
reasonable assurances that (A) transactions are executed in accordance with management’s general or
specific authorization; (B) transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles in the United
States and to maintain accountability for assets; (C) access to assets is permitted only in
accordance with management’s general or specific authorization; and (D) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Except as disclosed in the Registration Statement, in the General
Disclosure Package and in the Prospectus, the Company’s
11
internal control over financial reporting is effective and none of the Company, its board of
directors and audit committee is aware of any “significant deficiencies” or “material weaknesses”
(each as defined by the Public Company Accounting Oversight Board) in its internal control over
financial reporting, or any fraud that involves management or other employees of the Company who
have a significant role in the Company’s internal controls; and since the end of the latest audited
fiscal year, there has been no change in the Company’s internal control over financial reporting
(whether or not remediated) that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting. The Company’s board of directors
has, subject to the exceptions, cure periods and the phase in periods specified in the applicable
stock exchange rules (“Exchange Rules”), validly appointed an audit committee to oversee internal
accounting controls whose composition satisfies the applicable requirements of the Exchange Rules
and the Company’s board of directors and/or the audit committee has adopted a charter that
satisfies the requirements of the Exchange Rules.
(x) The Company’s board of directors has validly appointed an audit committee whose
composition satisfies the applicable requirements of the NASDAQ Global Market and the Company’s
board of directors and/or the audit committee has adopted a charter that satisfies the applicable
requirements of the NASDAQ Global Market. Neither the Company’s board of directors nor the audit
committee has been informed, nor is the Company aware, of (A) any significant deficiencies in the
design or operation of the Company’s internal controls which could adversely affect the Company’s
ability to record, process, summarize and report financial data or any material weakness in the
Company’s internal controls; or (B) any fraud, whether or not material, that involves management or
other employees of the Company who have a significant role in the Company’s internal controls.
(y) No relationship, direct or indirect, exists between or among the Company and its
subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of
the Company, on the other hand, which is required to be described in the Registration Statement,
the General Disclosure Package and the Prospectus which is not so described. The Company has not,
directly or indirectly, extended or maintained credit, or arranged for the extension of credit, or
renewed an extension of credit, in the form of a personal loan to or for any of its directors or
executive officers in violation of applicable laws, including Section 402 of the Xxxxxxxx-Xxxxx
Act.
(z) Except as described in the Registration Statement, the General Disclosure Package and the
Prospectus, the Company and its subsidiaries: (A) are and at all times have been in full compliance
with all statutes, rules, regulations, or guidances applicable to Company and its subsidiaries and
the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any
product manufactured or distributed by the Company (“Applicable Laws”), except as could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Change;
(B) have not received any notice of adverse finding, warning letter, untitled letter or other
correspondence or notice from the U.S. Food and Drug Administration or any other federal, state or
foreign governmental authority having authority over the Company (“Governmental Authority”)
alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by
any such Applicable Laws (“Authorizations”); (C) possess all
12
material Authorizations and such Authorizations are valid and in full force and effect and are
not in violation of any term of any such Authorizations; (D) have not received notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
Governmental Authority or third party alleging that any product operation or activity is in
violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental
Authority or third party is considering any such claim, litigation, arbitration, action, suit,
investigation or proceeding; (E) have not received notice that any Governmental Authority has
taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
and the Company has no knowledge that any such Governmental Authority is considering such action;
and (F) have filed, obtained, maintained or submitted all material reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments as required by
any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct
in all material respects on the date filed (or were corrected or supplemented by a subsequent
submission).
(aa) The studies, tests and preclinical and clinical trials conducted by or on behalf of the
Company and its subsidiaries were and, if still pending, are, in all material respects, being
conducted in accordance with experimental protocols, procedures and controls pursuant to accepted
professional scientific standards and all Applicable Laws and Authorizations, including, without
limitation, the Federal Food, Drug and Cosmetic Act; the descriptions of the results of such
studies, tests and trials contained in the Registration Statement, the General Disclosure Package
and the Prospectus are accurate and complete in all material respects and fairly present the data
derived from such studies, tests and trials; except to the extent disclosed in the Registration
Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any
studies, tests or trials the results of which the Company believes reasonably call into question
the study, test, or trial results described or referred to in the Registration Statement, the
General Disclosure Package and the Prospectus when viewed in the context in which such results are
described and the clinical state of development; and neither the Company nor any of its
subsidiaries have received any notices or correspondence from any Governmental Authority requiring
the termination, suspension or material modification of any studies, tests or preclinical or
clinical trials conducted by or on behalf of the Company or any of its subsidiaries.
(bb) The Company and its subsidiaries (A) are in compliance with any and all applicable
federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (collectively, “Environmental Laws”); (B) have received and are in
material compliance with all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their business; and (C) have not received notice of any actual or
potential liability for the investigation or remediation of any disposal or release of hazardous or
toxic substances or wastes, pollutants or contaminants, except in any such case for any such
failure to comply, or failure to receive required permits, licenses or approvals, or liability as
would not, individually or in the aggregate, result in a Material Adverse Change.
(cc) The documents incorporated by reference in the General Disclosure Package and in the
Prospectus, when they became effective or were filed with the Commission, as the case may be,
conformed in all material respects to the requirements of the Securities Act
13
or the Exchange Act, as applicable, and were filed on a timely basis with the Commission (or
if not timely filed, the failure to timely file was waived by the staff of the Commission), and
none of such documents contained an untrue statement of a material fact or omitted to state a
material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; any further documents so filed and incorporated by reference
in the General Disclosure Package or in the Prospectus, when such documents are filed with the
Commission, will conform in all material respects to the requirements of the Exchange Act, and will
not contain an untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not
misleading.
(dd) The Company and its subsidiaries (A) are in compliance, in all material respects, with
any and all applicable foreign, federal, state and local laws, rules, regulations, treaties,
statutes and codes promulgated by any and all governmental authorities (including pursuant to the
Occupational Health and Safety Act) relating to the protection of human health and safety in the
workplace (“Occupational Laws”); (B) have received all material permits, licenses or other
approvals required of it under applicable Occupational Laws to conduct their business as currently
conducted; and (C) are in compliance, in all material respects, with all terms and conditions of
such permit, license or approval. No action, proceeding, revocation proceeding, writ, injunction or
claim is pending or, to the Company’s knowledge, threatened against the Company or any of its
subsidiaries relating to Occupational Laws, and the Company does not have knowledge of any facts,
circumstances or developments relating to its operations or cost accounting practices that could
reasonably be expected to form the basis for or give rise to such actions, suits, investigations or
proceedings.
(ee) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed
to by the Company, any of its subsidiaries, or any of their affiliates for employees or former
employees of the Company and its subsidiaries has been maintained in material compliance with its
terms and the requirements of any applicable statutes, orders, rules and regulations, including but
not limited to, ERISA and the Internal Revenue Code of 1986, as amended (the “Code”). No
prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has
occurred with respect to any such plan excluding transactions effected pursuant to a statutory or
administrative exemption; and for each such plan that is subject to the funding rules of Section
412 of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section
412 of the Code has been incurred, whether or not waived, and the fair market value of the assets
of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the
present value of all benefits accrued under such plan determined using reasonable actuarial
assumptions.
(ff) Except as set forth in the Registration Statement, the General Disclosure Package and the
Prospectus, neither the Company nor any subsidiary has granted rights to develop, manufacture,
produce, assemble, distribute, license, market or sell their products to any other person and is
not bound by any agreement that affects either the Company’s or any of its subsidiaries’ exclusive
right to develop, manufacture, produce, assemble, distribute, license, market or sell their
products.
14
(gg) Nothing has come to the attention of the Company that has caused the Company to believe
that the statistical and market-related data included in the Registration Statement, the General
Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and
accurate in all material respects.
(hh) Other than as contemplated by this Agreement or as otherwise set forth in the
Registration Statement, the General Disclosure Package and the Prospectus, neither the Company nor
any of its subsidiaries has incurred any liability for any finder’s or broker’s fee or agent’s
commission in connection with the execution and delivery of this Agreement or the consummation of
the transactions contemplated hereby.
(ii) Neither the Company nor any of its subsidiaries is presently doing business with the
government of Cuba or with any person or affiliate located in Cuba.
(jj) The Company and its subsidiaries carry, or are covered by, insurance issued by insurers
of nationally recognized financial responsibility in such amounts and covering such risks as is
adequate for the conduct of their business and the value of their properties and as is customary
for companies engaged in similar businesses in similar industries; and neither the Company nor any
of its subsidiaries has (A) received notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be made in order to continue such
insurance or (B) reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business. All such insurance is outstanding
and duly in force on the date hereof.
(kk) No labor problem or dispute with the employees of the Company or any of its subsidiaries
exists that could be reasonably expected to result in a Material Adverse Change or is, to the
knowledge of the Company, threatened or imminent.
(ll) Neither the Company, any of its subsidiaries, nor, to the best knowledge of the Company,
any director, officer, agent, employee or other person associated with or acting on behalf of the
Company or its subsidiaries has (A) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expense relating to political activity; (B) made any direct or
indirect unlawful payment to any foreign or domestic government official or employee from corporate
funds; (C) violated or is in violation of any provision of the Foreign Corrupt Practices Act of
1977; or (D) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.
(mm) The Company is not and, after giving effect to the offering and sale of the Securities,
will not be an “investment company,” as such term is defined in the Investment Company Act of 1940,
as amended.
(nn) Except as described in the Prospectus, no approval of the shareholders of the Company is
required for the Company to issue and deliver to the Underwriters the Securities, including such as
may be required pursuant to the rules and regulations of any trading market.
(oo) The conditions for use of Form S-3, set forth in the General Instructions thereto, have
been satisfied.
15
(pp) The Company is in compliance with all applicable provisions of the Xxxxxxxx-Xxxxx Act and
the rules and regulations of the Commission thereunder.
(qq) The Company has established and maintains disclosure controls and procedures (as defined
in Rules 13a-14 and 15d-14 under the Exchange Act) and such controls and procedures are effective
in ensuring that material information relating to the Company is made known to the principal
executive officer and the principal financial officer. The Company has utilized such controls and
procedures in preparing and evaluating the disclosures in the Registration Statement, in the
General Disclosure Package and in the Prospectus.
(rr) The Company and its board of directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or other similar anti-takeover provision under the
Company’s charter documents or the laws of its state of incorporation that is or could reasonably
be expected to become applicable to any of the Underwriters as a result of the Underwriters and the
Company fulfilling their obligations or exercising their rights under the Agreement, including,
without limitation, the Company’s issuance of the Securities and the Underwriters’ ownership of the
Securities.
(ss) Neither the Company nor, to its Knowledge, any of its directors, officers or controlling
persons has taken, directly or indirectly, any action intended to cause or result in, or which
might reasonably be expected to cause or result in, or which has constituted, stabilization or
manipulation, under the Act or otherwise, of the price of any security of the Company to facilitate
the sale or resale of the Securities.
4. Agreements of the Company. The Company agrees with each Underwriter as follows:
(a) Amendments and Supplements to Registration Statement. The Company shall not, either prior
to any effective date or thereafter during such period as the Prospectus is required by law to be
delivered (the “Prospectus Delivery Period”) in connection with sales of the Securities by an
Underwriter or dealer, amend or supplement to the Registration Statement, the General Disclosure
Package or the Prospectus, unless a copy of such amendment or supplement thereof shall first have
been submitted to the Representative within a reasonable period of time prior to the filing or, if
no filing is required, the use thereof and the Representative shall not have objected thereto in
good faith.
16
(b) Amendments and Supplements to the Registration Statement, the General Disclosure Package,
and the Prospectus and Other Securities Act Matters. If, during the Prospectus Delivery Period,
any event or development shall occur or condition exist as a result of which the General Disclosure
Package or the Prospectus as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances then prevailing or under which they were made, as the case may
be, not misleading, or if it shall be necessary to amend or supplement the General Disclosure
Package or the Prospectus, or to file under the Exchange Act any document incorporated by reference
in the General Disclosure Package or the Prospectus, in order to make the statements therein, in
the light of the circumstances then prevailing or under which they were made, as the case may be,
not misleading, or if in the opinion of the Representative it is otherwise necessary to amend or
supplement the Registration Statement, the General Disclosure Package or the Prospectus, or to file
under the Exchange Act any document incorporated by reference in the General Disclosure Package or
the Prospectus, or to file a new registration statement containing the Prospectus, in order to
comply with law, including in connection with the delivery of the Prospectus, the Company agrees to
(i) promptly notify the Representative of any such event or condition and (ii) promptly prepare
(subject to Section 4(a) and (g) hereof), file with the Commission (and use its best efforts to
have any amendment to the Registration Statement or any new registration statement to be declared
effective) and furnish at its own expense to the Underwriters and to dealers, amendments or
supplements to the Registration Statement, the General Disclosure Package or the Prospectus, or any
new registration statement, necessary in order to make the statements in the General Disclosure
Package or the Prospectus as so amended or supplemented, in the light of the circumstances then
prevailing or under which they were made, as the case may be, not misleading or so that the
Registration Statement, the General Disclosure Package or the Prospectus, as amended or
supplemented, will comply with law.
(c) Notifications to the Representative. The Company shall use its best efforts to cause the
Registration Statement to continue to be effective, and shall notify the Representative promptly,
and shall confirm such advice in writing, (i) when any post-effective amendment to the Registration
Statement has become effective and when any post-effective amendment thereto becomes effective,
(ii) of any request by the Commission for amendments or supplements to the Registration Statement
or the Prospectus or for additional information, (iii) of the commencement by the Commission or by
any state securities commission of any proceedings for the suspension of the qualification of any
of the Securities for offering or sale in any jurisdiction or of the initiation, or the
threatening, of any proceeding for that purpose, including, without limitation, the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or the
initiation of any proceedings for that purpose or the threat thereof, (iv) of the happening of any
event during the period mentioned in the second sentence of Section 4(f) hereof that in the
judgment of the Company makes any statement made in the Registration Statement or the Prospectus
untrue or that requires the making of any changes in the Registration Statement or the Prospectus
in order to make the statements therein, in light of the circumstances in which they are made, not
misleading and (v) of receipt by the Company or any representative of the Company of any other
communication from the Commission relating to the Company, the Registration Statement, any
preliminary prospectus or the Prospectus. If at any time the Commission shall issue any order
suspending the effectiveness of the Registration Statement, the Company shall use best efforts to
obtain the withdrawal of
17
such order at the earliest possible moment. The Company shall use its best efforts to comply
with the provisions of and make all requisite filings with the Commission pursuant to Rules 430A,
430B, 430C or 462(b) of the Rules and Regulations and to notify the Representative promptly of all
such filings.
(d) Executed Registration Statements. The Company shall furnish to the Representative,
without charge, for transmittal to each of the other Underwriters, two signed copies of the
Registration Statement and of any post-effective amendment thereto, including financial statements
and schedules, and all exhibits thereto (including any document filed under the Exchange Act and
deemed to be incorporated by reference into the Prospectus), and shall furnish to the
Representative, without charge, for transmittal to each of the other Underwriters, a copy of the
Registration Statement and any post-effective amendment thereto, including financial statements and
schedules but without exhibits.
(e) Undertakings. The Company shall comply with all the provisions of any undertakings
contained and required to be contained in the Registration Statement.
(f) Prospectus. Promptly after the date of this Agreement, and thereafter from time to time,
the Company shall deliver to each of the Underwriters, without charge, as many copies of the
Prospectus and any amendment or supplement thereto as the Representative may reasonably request.
The Company consents to the use of the Prospectus and any amendment or supplement thereto by the
Underwriters and by all dealers to whom the Securities may be sold, both in connection with the
offering or sale of the Securities and for any period of time thereafter during which the
Prospectus is required by law to be delivered in connection therewith. If during such period of
time any event shall occur that in the judgment of the Company or counsel to the Underwriters
should be set forth in the Prospectus in order to make any statement therein, in the light of the
circumstances under which it was made, not misleading, or if it is necessary to supplement or amend
the Prospectus to comply with law, the Company shall forthwith prepare and duly file with the
Commission an appropriate supplement or amendment thereto, and shall deliver to each of the
Underwriters, without charge, such number of copies thereof as the Representative may reasonably
request. The Company shall not file any document under the Exchange Act before the termination of
the offering of the Securities by the Underwriters if such document would be deemed to be
incorporated by reference into the Prospectus unless a copy thereof shall first have been submitted
to the Representative within a reasonable period of time prior to the filing thereof and the
Representative shall not have objected thereto in good faith.
(g) Permitted Free Writing Prospectuses. The Company represents and agrees that it has not
made and, unless it obtains the prior consent of the Representative, will not make, any offer
relating to the Securities that would constitute a “free writing prospectus” as defined in Rule 405
of the Rules and Regulations, required to be retained by the Company under Rule 433 of the Rules
and Regulations; provided that the prior written consent of the Representative hereto shall be
deemed to have been given in respect of the Issuer Free Writing Prospectuses included in
Schedule III hereto. Any such free writing prospectus consented to by the Representative
is herein referred to as a “Permitted Free Writing Prospectus.” The Company agrees that (i) it has
treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer
Free Writing Prospectus, and (ii) has complied and will comply, as the
18
case may be, with the requirements of Rules 164 and 433 of the Act applicable to any Permitted
Free Writing Prospectus, including in respect of timely filing with the Commission, legending and
record keeping.
(h) Compliance with Blue Sky Laws. Prior to any public offering of the Securities by the
Underwriters, the Company shall cooperate with the Representative and counsel to the Underwriters
in connection with the registration or qualification (or the obtaining of exemptions from the
application thereof) of the Securities for offer and sale under the securities or Blue Sky laws of
such jurisdictions as the Representative may request, including, without limitation, jurisdictions
outside the United States; provided, however, that in no event shall the Company be obligated to
qualify to do business in any jurisdiction where it is not now so qualified or to take any action
which would subject it to general service of process in any jurisdiction where it is not now so
subject.
(i) Delivery of Financial Statements. During the period of five years commencing on the
effective date of the Registration Statement applicable to the Underwriters, the Company shall
furnish to the Representative and each other Underwriter who may so request copies of such
financial statements and other periodic and special reports as the Company may from time to time
distribute generally to the holders of any class of its capital stock, and will furnish to the
Representative and each other Underwriter who may so request a copy of each annual or other report
it shall be required to file with the Commission.
(j) Availability of Earnings Statements. The Company shall make generally available to
holders of its securities as soon as may be practicable but in no event later than the last day of
the fifteenth full calendar month following the calendar quarter in which the most recent effective
date occurs in accordance with Rule 158 of the Rules and Regulations, an earnings statement (which
need not be audited but shall be in reasonable detail) for a period of 12 months ended commencing
after the date hereof, and satisfying the provisions of Section 11(a) of the Act (including Rule
158 of the Rules and Regulations).
(k) Reimbursement of Certain Expenses. Whether or not any of the transactions contemplated by
this Agreement are consummated or this Agreement is terminated, the Company shall pay, or reimburse
if paid by the Representative, all costs and expenses incident to the performance of the
obligations of the Company under this Agreement, including but not limited to costs and expenses of
or relating to (i) the preparation, printing and filing of the Registration Statement and exhibits
to it, each preliminary prospectus, each Permitted Free Writing Prospectus, the Prospectus and any
amendment or supplement to the Registration Statement or the Prospectus, (ii) the preparation and
delivery of certificates representing the Securities, (iii) the printing of this Agreement, the
Agreement Among Underwriters, any Dealer Agreements and any Underwriters’ Questionnaire, (iv)
furnishing (including costs of shipping, mailing and courier) such copies of the Registration
Statement, the Prospectus, any preliminary prospectus and any Permitted Free Writing Prospectus,
and all amendments and supplements thereto, as may be requested for use in connection with the
offering and sale of the Securities by the Underwriters or by dealers to whom Securities may be
sold, (v) the listing or quotation of the Securities on the NASDAQ Global Market, (vi) any filings
required to be made by the Representative with FINRA, and the fees, disbursements and other charges
of counsel for the Underwriters in connection therewith, (vii) the registration or qualification of
the Securities for
19
offer and sale under the securities or Blue Sky laws of such jurisdictions designated pursuant
to Section 4(h) hereof, including the fees, disbursements and other charges of counsel to the
Underwriters in connection therewith, and, if requested by the Representative, the preparation and
printing of preliminary, supplemental and final Blue Sky memoranda, (viii) counsel to the Company,
(ix) DTC and the transfer agent for the Securities, (x) the Accountants, (xi) the marketing of the
offering by the Company, including, without limitation, all costs and expenses of commercial
airline tickets, hotels, meals and other travel expenses of officers, employees, agents and other
representatives of the Company (but not officers, employees, agents or other representatives of the
Representative), (xii) all fees, costs and expenses for consultants used by the Company in
connection with the offering, and (xiii) reasonable fees and out-of-pocket expenses incurred by the
Underwriters, including fees, disbursements and other charges of counsel to the Underwriters (in
addition to (vi) and (vii) above), in an amount not to exceed $100,000 without the prior written
consent of the Company.
(l) Reimbursement of Expenses upon Termination of Agreement. If this Agreement shall be
terminated by the Company pursuant to any of the provisions hereof or if for any reason the
Company shall be unable to perform its obligations or to fulfill any conditions hereunder or if the
Underwriters shall terminate this Agreement pursuant to Section 7, the Company shall reimburse the
several Underwriters for all out-of-pocket expenses (including the fees, disbursements and other
charges of counsel to the Underwriters) reasonably incurred by them in connection herewith.
(m) No Stabilization or Manipulation. The Company shall not at any time, directly or
indirectly, take any action intended to cause or result in, or which might reasonably be expected
to cause or result in, or which will constitute, stabilization or manipulation, under the Act or
otherwise, of the price of the shares of Common Stock to facilitate the sale or resale of any of
the Securities.
(n) Use of Proceeds. The Company shall apply the net proceeds from the offering and sale of
the Securities to be sold by the Company in the manner set forth in the Prospectus under “Use of
Proceeds”.
(o) Lock-Up Agreements of Company, Management and Affiliates. The Company shall not, and
shall cause each of its executive officers and directors to enter into agreements with the
Representative in the form set forth in Exhibit A to the effect that they shall not, for a
period of 90 days after the date of the Prospectus (the “Lock-Up Period”), without the prior
written consent of the Representative (which consent may be withheld in its sole discretion), (1)
offer to sell, sell, pledge, contract to sell, purchase any option to sell, grant any option for
the purchase of, lend, or otherwise dispose of, or require the Company to file with the Commission
a registration statement under the Act to register, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock or warrants or other rights to
acquire shares of Common Stock of which they are now, or may in the future become, the beneficial
owner (within the meaning of Rule 13d-3 under the Exchange Act) (other than (A) the issuance of
units in drilling partnerships sponsored by the Company or Common Stock issued to acquire interests
in outstanding drilling partnerships sponsored by the Company or (B) pursuant to employee stock
option plans or Rule10b5-1 plans existing on, or upon the conversion or exchange of convertible or
exchangeable securities outstanding as of, the date of
20
the Prospectus) or (2) enter into any swap or other derivatives transaction that transfers to
another, in whole or in part, any of the economic benefits or risks of ownership of such shares of
Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by
delivery of Common Stock or other securities, in cash or otherwise; except that if (i) during the
period that begins on the date that is 15 calendar days plus three business days before the last
day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an
earnings release or material news or a material event relating to the Company occurs, or (ii) prior
to the expiration of the Lock-Up Period, the Company announces that it will release earnings
results during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions
imposed by this section shall continue to apply until the expiration of the date that is 15
calendar days plus three business days after the date on which the issuance of the earnings release
or the material news or material event occurs, provided, however, this provision will not apply if,
within three days of the termination of the Lock-Up Period, the Company delivers to the
Representative a certificate, signed by the Chief Financial Officer or Chief Executive Officer of
the Company, certifying on behalf of the Company that the Company’s shares of Common Stock are, as
of the date of delivery of such certificate, “actively trading securities,” as defined in
Regulation M under the Exchange Act.
5. Conditions of the Obligations of the Underwriters. The obligations of each
Underwriter hereunder are subject to the following conditions:
(a) Post Effective Amendments and Prospectus Filings. Notification that the Registration
Statement has become effective shall be received by the Representative not later than 6:00 p.m.,
New York time, on the date of this Agreement or at such later date and time as shall be consented
to in writing by the Representative and all filings made pursuant to Rule 424 of the Rules and
Regulations and Rules 430A, 430B or 430C, as applicable, shall have been made or will be made prior
to the Closing Date and the Second Closing Date, as the case may be, in accordance with all such
applicable rules.
(b) No Stop Orders, Requests for Information and No Amendments. (i) No stop order suspending
the effectiveness of the Registration Statement shall have been issued and no proceedings for that
purpose shall be pending or are, to the best knowledge of the Company, threatened by the
Commission, (ii) no order suspending the qualification or registration of the Securities under the
securities or Blue Sky laws of any jurisdiction shall be in effect and no proceeding for such
purpose shall be pending before or threatened or contemplated by the authorities of any such
jurisdiction, (iii) any request for additional information on the part of the staff of the
Commission or any such authorities shall have been complied with to the satisfaction of the staff
of the Commission or such authorities and (iv) after the date hereof no amendment or supplement to
the Registration Statement or the Prospectus shall have been filed unless a copy thereof was first
submitted to the Representative and the Representative did not object thereto in good faith, and
the Representative shall have received certificates, dated the Closing Date and the Second Closing
Date, as the case may be, and signed by the Chief Executive Officer or the Chairman of the Board of
Directors and the Chief Financial Officer of the Company (who may, as to proceedings threatened,
rely upon the best of their information and belief), to the effect of clauses (i), (ii) and (iii).
21
(c) No Material Adverse Changes. Since the respective dates as of which information is given
in the Registration Statement and the Prospectus, except as set forth or incorporated by reference
in the Prospectus (i) there shall not have been a Material Adverse Change, (ii) the Company shall
not have incurred any material liabilities or obligations, direct or contingent, (iii) the Company
shall not have entered into any material transactions not in the ordinary course of business other
than pursuant to this Agreement and the transactions referred to herein, (iv) the Company has not
issued any securities (other than the Securities) or declared or paid any dividend or made any
distribution in respect of its capital stock of any class or debt (long-term or short-term), and
(v) no material amount of the assets of the Company or any of the subsidiaries shall have been
pledged, mortgaged or otherwise encumbered.
(d) No Actions, Suits or Proceedings. Since the respective dates as of which information is
given or incorporated by reference in the Registration Statement and the Prospectus, there shall
have been no actions, suits or proceedings instituted, or to the Company’s knowledge, threatened
against or affecting, the Company or the subsidiaries or any of their respective officers in their
capacity as such, before or by any Federal, state or local court, commission, regulatory body,
administrative agency or other governmental body, domestic or foreign.
(e) All Representations True and Correct and All Conditions Fulfilled. Each of the
representations and warranties of the Company contained herein shall be true and correct in all
material respects at the Closing Date and the Second Closing Date, as the case may be, as if made
at such date, and all covenants and agreements contained herein to be performed by the Company and
all conditions contained herein to be fulfilled or complied with by the Company at or prior to the
Closing Date and the Second Closing Date, as the case may be, shall have been duly performed,
fulfilled or complied with.
(f) Opinion of Counsel to the Company. The Representative shall have received the opinion and
letter, each dated the Closing Date and the Second Closing Date, as the case may be, reasonably
satisfactory in form and substance to counsel for the Underwriters, from Xxxxxx LLP, counsel to the
Company, to the effect set forth in Exhibit B.
(g) Opinion of Counsel to the Underwriters. The Representative shall have received the
opinion and letter, each dated the Closing Date and the Second Closing Date, as the case may be,
from Xxxxxxx Procter LLP, counsel to the Underwriters, with respect to the Registration Statement,
the Prospectus and this Agreement, which opinion and letter shall be satisfactory in all respects
to the Representative.
(h) Accountants’ Comfort Letter. On the date of the Prospectus, the Representative shall have
received from the Accountants a letter dated the date of its delivery, addressed to the
Representative, in form and substance reasonably satisfactory to the Representative, containing
statements and information of the type ordinarily included in accountant’s “comfort letters” to
underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor
bulletin), with respect to the audited and unaudited financial statements and certain financial
information contained or incorporated by reference in the Registration Statement and the
Prospectus. At the Closing Date and the Second Closing Date, as the case may be, the
Representative shall have received from the Accountants a letter dated such
22
date, in form and substance reasonably satisfactory to the Representative, to the effect that
they reaffirm the statements made in the letter furnished by them pursuant to the preceding
sentence, except that the specified date referred to therein for the carrying out of procedures
shall be no more than three business days prior to the Closing Date and the Second Closing Date, as
the case may be.
(i) Officers’ Certificates. At the Closing Date and the Second Closing Date, as the case may
be, there shall be furnished to the Representative an accurate certificate, dated the date of its
delivery, signed by each of the Chief Executive Officer and the Chief Financial Officer of the
Company, in form and substance satisfactory to the Representative, to the effect that:
(i) each signer of such certificate has carefully examined the Registration Statement and the
Prospectus (including any documents filed under the Exchange Act and deemed to be incorporated by
reference into the Prospectus);
(ii) there has not been a Material Adverse Change;
(iii) each of the representations and warranties of the Company contained in this Agreement
are, at the time such certificate is delivered, true and correct in all material respects; and
(iv) each of the covenants required herein to be performed by the Company on or prior to the
date of such certificate has been duly, timely and fully performed and each condition herein
required to be complied with by the Company on or prior to the delivery of such certificate has
been duly, timely and fully complied with.
(j) Lock-Up Agreements. On or prior to the Closing Date, the Representative shall have
received the executed “lock-up” agreements referred to in Section 4(o).
(k) Compliance with Blue Sky Laws. The Securities shall be qualified for sale in such states
and jurisdictions as the Representative may reasonably request, including, without limitation,
jurisdictions outside the United States, and each such qualification shall be in effect and not
subject to any stop order or other proceeding on the Closing Date and the Second Closing Date, as
the case may be.
(l) Stock Exchange Listing. The Securities shall have been duly authorized for listing or
quotation on the NASDAQ Global Market, subject only to notice of issuance.
(m) Chief Financial Officer’s Certificate. At the Closing Date and the Second Closing Date,
as the case may be, there shall be furnished to the Representative an accurate certificate, dated
the date of its delivery, signed by the Chief Financial Officer of the Company, in form and
substance satisfactory to the Representative and as set forth on Exhibit C attached hereto:
(n) Secretary’s Certificate. At the Closing Date and the Second Closing Date, as the case may
be, there shall be furnished to the Representative an accurate certificate, dated the date of its
delivery, signed by the Secretary of the Company, in form and substance
23
satisfactory to the Representative, certifying the certificate of incorporation, bylaws and
resolutions of the board of directors or a committee thereof.
(o) Company Certificates. The Company shall have furnished to the Representative such
certificates, in addition to those specifically mentioned herein, as the Representative may have
reasonably requested as to the accuracy and completeness at the Closing Date and the Second Closing
Date, as the case may be, of any statement in the Registration Statement or the Prospectus or any
documents filed under the Exchange Act and deemed to be incorporated by reference into the
Prospectus, as to the accuracy at the Closing Date and the Second Closing Date, as the case may be,
of the representations and warranties of the Company herein, as to the performance by the Company
of its obligations hereunder, or as to the fulfillment of the conditions concurrent and precedent
to the obligations hereunder of the Representative.
6. Indemnification.
(a) Indemnification of the Underwriters. The Company shall indemnify and hold harmless each
Underwriter, the directors, officers, employees, counsel and agents of each Underwriter and each
person, if any, who controls each Underwriter within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act from and against any and all losses, claims, liabilities, expenses
and damages (including any and all investigative, legal and other expenses reasonably incurred in
connection with, and any amount paid in settlement of, any action, suit or proceeding between any
of the indemnified parties and any indemnifying parties or between any indemnified party and any
third party, or otherwise, or any claim asserted), to which they, or any of them, may become
subject under the Act, the Exchange Act or other Federal or state statutory law or regulation, at
common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out
of or are based on (i) any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement (or any amendment thereto), including any information
deemed to be a part thereof pursuant to Rules 430A, 430B or 430C, as applicable, including all
documents incorporated therein by reference, or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not
misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in
any preliminary prospectus, any preliminary prospectus supplement, any Issuer Free Writing
Prospectus or the Prospectus (or any amendment or supplement thereto) or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading or (iii) any untrue statement
or alleged untrue statement of a material fact contained in any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the
offering of the Securities, including any roadshow or investor presentations made to investors by
the Company (whether in person or electronically) or the omission or alleged omission therefrom of
a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that the Company shall
not be liable to the extent that such loss, claim, liability, expense or damage arises from the
sale of the Securities in the public offering to any person by an Underwriter and is based on an
untrue statement or omission or alleged untrue statement or omission made in reliance on and in
conformity with information relating to any Underwriter furnished in writing to the Company by the
Representative on behalf
24
of any Underwriter expressly for inclusion in the Registration Statement, any preliminary
prospectus, any Issuer Free Writing Prospectus or the Prospectus. If multiple claims are brought
against any Underwriter, the directors, officers, employees, counsel and agents of such Underwriter
and any person, if any, who controls such Underwriter within the meaning of Section 15 of the Act
or Section 20 of the Exchange Act, in an arbitration proceeding, and indemnification is permitted
under applicable law and is provided for under this Agreement with respect to at least one such
claim, the Company agrees that any arbitration award shall be conclusively deemed to be based on
claims as to which indemnification is permitted and provided for, except to the extent the
arbitration award expressly states that the award, or any portion thereof, is based solely on a
claim as to which indemnification is not available. This indemnity agreement will be in addition
to any liability that the Company might otherwise have.
(b) Indemnification of the Company. Each Underwriter, severally and not jointly, shall
indemnify and hold harmless the Company, its agents, each person, if any, who controls the Company
within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, each director of the
Company and each officer of the Company who signs the Registration Statement to the same extent as
the foregoing indemnity from the Company to each Underwriter, but only insofar as losses, claims,
liabilities, expenses or damages arise out of or are based on any untrue statement or omission or
alleged untrue statement or omission made in reliance on and in conformity with information
relating to each Underwriter furnished in writing to the Company by the Representative on behalf of
such Underwriter expressly for use in the Registration Statement, any preliminary prospectus or the
Prospectus. This indemnity will be in addition to any liability that each Underwriter might
otherwise have.
(c) Indemnification Procedures. Any party that proposes to assert the right to be indemnified
under this Section 6 shall, promptly after receipt of notice of commencement of any action against
such party in respect of which a claim is to be made against an indemnifying party or parties under
this Section 6, notify each such indemnifying party of the commencement of such action, enclosing a
copy of all papers served, but the omission so to notify such indemnifying party shall not relieve
the indemnifying party from any liability that it may have to any indemnified party under the
foregoing provisions of this Section 6 unless, and only to the extent that, such omission results
in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action
is brought against any indemnified party and it notifies the indemnifying party of its
commencement, the indemnifying party will be entitled to participate in and, to the extent that it
elects by delivering written notice to the indemnified party promptly after receiving notice of the
commencement of the action from the indemnified party, jointly with any other indemnifying party
similarly notified, to assume the defense of the action, with counsel satisfactory to the
indemnified party, and after notice from the indemnifying party to the indemnified party of its
election to assume the defense, the indemnifying party will not be liable to the indemnified party
for any legal or other expenses except as provided below and except for the reasonable costs of
investigation subsequently incurred by the indemnified party in connection with the defense. The
indemnified party will have the right to employ its own counsel in any such action, but the fees,
expenses and other charges of such counsel will be at the expense of such indemnified party unless
(i) the employment of counsel by the indemnified party has been authorized in writing by the
indemnifying party, (ii) the indemnified party has reasonably concluded (based on advice of
counsel) that there may be legal defenses available to it or other indemnified parties that are
different from or in addition to those available to the
25
indemnifying party, (iii) a conflict or potential conflict exists (based on advice of counsel
to the indemnified party) between the indemnified party and the indemnifying party (in which case
the indemnifying party shall not have the right to direct the defense of such action on behalf of
the indemnified party) or (iv) the indemnifying party has not in fact employed counsel to assume
the defense of such action within a reasonable time after receiving notice of the commencement of
the action, in each of which cases the reasonable fees, disbursements and other charges of counsel
shall be at the expense of the indemnifying party or parties. It is understood that the
indemnifying party or parties shall not, in connection with any proceeding or related proceedings
in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of
more than one separate firm admitted to practice in such jurisdiction at any one time for all such
indemnified party or parties. All such fees, disbursements and other charges shall be reimbursed
by the indemnifying party promptly as they are incurred. An indemnifying party shall not be liable
for any settlement of any action or claim effected without its written consent (which consent will
not be unreasonably withheld or delayed). No indemnifying party shall, without the prior written
consent of each indemnified party, settle or compromise or consent to the entry of any judgment in
any pending or threatened claim, action or proceeding relating to the matters contemplated by this
Section 6 (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent includes an unconditional release of each indemnified party from all
liability arising or that may arise out of such claim, action or proceeding.
(d) Contribution. In order to provide for just and equitable contribution in circumstances in
which the indemnification provided for in the foregoing paragraphs of this Section 6 is applicable
in accordance with its terms but for any reason is held to be unavailable from the Company or the
Underwriters, the Company and the Underwriters shall contribute to the total losses, claims,
liabilities, expenses and damages (including any investigative, legal and other expenses reasonably
incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding
or any claim asserted, but after deducting any contribution received by the Company from persons
other than the Underwriters, such as persons who control the Company within the meaning of the Act,
officers of the Company who signed the Registration Statement and directors of the Company, who
also may be liable for contribution) to which the Company and the Underwriters may be subject in
such proportion as shall be appropriate to reflect the relative benefits received by the Company on
the one hand and the Underwriters on the other. The relative benefits received by the Company on
the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the
total net proceeds from the offering (before deducting expenses) received by the Company bear to
the total underwriting discounts and commissions received by the Underwriters, in each case as set
forth in the table on the cover page of the Prospectus. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall
be made in such proportion as is appropriate to reflect not only the relative benefits referred to
in the foregoing sentence but also the relative fault of the Company, on the one hand, and the
Underwriters, on the other, with respect to the statements or omissions which resulted in such
loss, claim, liability, expense or damage, or action in respect thereof, as well as any other
relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to whether the untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to information supplied by the
Company or Representative on behalf of the Underwriters, the intent of the parties and their
relative knowledge, access to information and opportunity to correct or prevent such statement or
26
omission. The Company and the Underwriters agree that it would not be just and equitable if
contributions pursuant to this Section 6(d) were to be determined by pro rata allocation or by any
other method of allocation (even if the Underwriters were treated as one entity for such purpose)
which does not take into account the equitable considerations referred to herein. The amount paid
or payable by an indemnified party as a result of the loss, claim, liability, expense or damage, or
action in respect thereof, referred to above in this Section 6(d) shall be deemed to include, for
purpose of this Section 6(d), any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section 6(d), no Underwriter shall be required to contribute any amount in
excess of the underwriting discounts and commissions received by it, and no person found guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters’ obligation to contribute as provided in this Section 6(d) are several in proportion
to their respective underwriting obligations and not joint. For purposes of this Section 6(d), any
person who controls a party to this Agreement within the meaning of the Act will have the same
rights to contribution as that party, and each officer of the Company who signed the Registration
Statement will have the same rights to contribution as the Company, subject in each case to the
provisions hereof. Any party entitled to contribution, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim for contribution may be
made under this Section 6(d), will notify any such party or parties from whom contribution may be
sought, but the omission so to notify will not relieve the party or parties from whom contribution
may be sought from any other obligation it or they may have under this Section 6(d). No party will
be liable for contribution with respect to any action or claim settled without its written consent
(which consent will not be unreasonably withheld).
(e) Survival. The indemnity and contribution agreements contained in this Section 6 and the
representations and warranties of the Company contained in this Agreement shall remain operative
and in full force and effect regardless of (i) any investigation made by or on behalf of the
Underwriters, (ii) acceptance of any of the Securities and payment therefor or (iii) any
termination of this Agreement.
7. Termination. The obligations of the several Underwriters under this Agreement may
be terminated at any time prior to the Closing Date and the Second Closing Date, as the case may
be, by notice to the Company from the Representative without liability on the part of any
Underwriter to the Company, if, prior to delivery and payment for the Securities, in the sole
judgment of the Representative, any of the following shall occur:
(a) trading or quotation in any of the equity securities of the Company shall have been
suspended or limited by the Commission or by an exchange or otherwise;
(b) trading in securities generally on the New York Stock Exchange or the NASDAQ Global Market
shall have been suspended or limited or minimum or maximum prices shall have been generally
established on such exchange, or additional material governmental restrictions, not in force on the
date of this Agreement, shall have been imposed upon trading in securities generally by such
exchange or by order of the Commission or any court or other governmental authority;
27
(c) a general banking moratorium shall have been declared by any of Federal or New York
authorities;
(d) the United States shall have become engaged in new hostilities, there shall have been an
escalation in hostilities involving the United States or there shall have been a declaration of a
national emergency or war by the United States or there shall have occurred such a material adverse
change in general economic, political or financial conditions, including, without limitation, as a
result of terrorist activities after the date hereof (or the effect of international conditions on
the financial markets in the United States shall be such), or any other calamity or crisis shall
have occurred, the effect of any of which is such as to make it impracticable or inadvisable to
market the Securities on the terms and in the manner contemplated by the Prospectus;
(e) if the Company or any of its subsidiaries shall have sustained a loss material or
substantial to the Company or any of its subsidiaries by reason of flood, fire, accident,
hurricane, earthquake, theft, sabotage, or other calamity or malicious act, whether or not such
loss shall have been insured, the effect of any of which is such as to make it impracticable or
inadvisable to market the Securities on the terms and in the manner contemplated by the Prospectus;
or
(f) if there shall have been a Material Adverse Change.
8. Substitution of Underwriters. If any one or more of the Underwriters shall fail or
refuse to purchase any of the Securities which it or they have agreed to purchase hereunder, and
the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but
failed or refused to purchase is not more than one-tenth of the aggregate number of Securities, the
other Underwriters shall be obligated, severally, to purchase the Securities which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase, in the proportions which the
number of Securities which they have respectively agreed to purchase pursuant to Section 1 bears to
the aggregate number of Securities which all such non-defaulting Underwriters have so agreed to
purchase, or in such other proportions as the Representative may specify; provided that in no event
shall the maximum number of Securities which any Underwriter has become obligated to purchase
pursuant to Section 1 be increased pursuant to this Section 8 by more than one-ninth of the number
of Securities agreed to be purchased by such Underwriter without the prior written consent of such
Underwriter. If any Underwriter or Underwriters shall fail or refuse to purchase any Securities
and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but
failed or refused to purchase exceeds one-tenth of the aggregate number of the Securities and
arrangements satisfactory to the Company and the Representative for the purchase of such
Securities are not made within 48 hours after such default, this Agreement will terminate without
liability on the part of any non-defaulting Underwriter, or the Company for the purchase or sale of
any Securities under this Agreement. In any such case either the Representative or the Company
shall have the right to postpone the Closing Date, but in no event for longer than seven days, in
order that the required changes, if any, in the Registration Statement and in the Prospectus or in
any other documents or arrangements may be effected. Any action taken pursuant to this Section 8
shall not relieve any defaulting Underwriter from liability in respect of any default of such
Underwriter under this Agreement.
28
9. Miscellaneous.
(a) Notices. Notice given pursuant to any of the provisions of this Agreement shall be in
writing and, unless otherwise specified, shall be mailed, hand delivered or telecopied (a) if to
the Company, at the office of Clinical Data, Inc., Xxx Xxxxxxx Xxxxxx, Xxxxx 000, Xxxxxx,
Xxxxxxxxxxxxx 00000, Attention: Chief Executive Officer, with a copy to (which shall not constitute
notice hereunder): Xxxxxx LLP, 000 Xxxxxxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx 00000-0000, Attention:
Xxxx Xxxxx, Esq., or (b) if to the Underwriters c/o the Representative, at the office of BMO
Capital Markets Corp., 0 Xxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000, Attention: Xxxxxx Xxxxxxx, with a
copy to (which shall not constitute notice hereunder): Xxxxxxx Procter LLP, The New York Times
Building, 000 Xxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000. Attention: Xxxxxxx X. Xxxxxx, Esq. Any
such notice shall be effective only upon receipt. Any notice under Section 7 may be made by
telecopy or telephone, but if so made shall be subsequently confirmed in writing.
(b) No Third Party Beneficiaries. This Agreement has been and is made solely for the benefit
of the several Underwriters, the Company and of the controlling persons, directors and officers
referred to in Section 6, and their respective successors and assigns, and no other person shall
acquire or have any right under or by virtue of this Agreement. The term “successors and assigns”
as used in this Agreement shall not include a purchaser of Securities from the Underwriters in
his, her or its capacity as such a purchaser, as such purchaser of Securities from any of the
several Underwriters.
(c) Survival of Representations and Warranties. All representations, warranties and
agreements of the Company contained herein or in certificates or other instruments delivered
pursuant hereto, shall remain operative and in full force and effect regardless of any
investigation made by or on behalf of any Underwriter or any of their controlling persons and shall
survive delivery of and payment for the Securities hereunder.
(d) Disclaimer of Fiduciary Relationship. The Company acknowledges and agrees that (i) the
purchase and sale of the Securities pursuant to this Agreement, including the determination of the
public offering price of the Securities and any related discounts and commissions, is an
arm’s-length commercial transaction between the Company, on the one hand, and the Underwriters, on
the other hand, (ii) in connection with the offering contemplated by this Agreement and the process
leading to such transaction, each of the Underwriters is and has been acting solely as a principal
and is not the agent or fiduciary of the Company or its securityholders, creditors, employees or
any other party, (iii) none of the Underwriters has assumed nor will it assume any advisory or
fiduciary responsibility in favor of the Company with respect to the offering of the Securities
contemplated by this Agreement or the process leading thereto (irrespective of whether any
Underwriter or its affiliates has advised or is currently advising the Company on other matters)
and the Underwriters have no obligation to the Company with respect to the offering of the
Securities contemplated by this Agreement except the obligations expressly set forth in this
Agreement, (iv) each of the Underwriters and their respective affiliates may be engaged in a broad
range of transactions that involve interests that differ from those of the Company, and (v) the
Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the
offering contemplated by this Agreement
29
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the
extent it deemed appropriate.
(e) Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN
SUCH STATE. Each party hereto hereby irrevocably submits for purposes of any action arising from
this Agreement brought by the other party hereto to the jurisdiction of the courts of New York
State located in the Borough of Manhattan and the U.S. District Court for the Southern District of
New York. This Agreement may be signed in two or more counterparts with the same effect as if the
signatures thereto and hereto were upon the same instrument.
(f) Survival of Provisions Upon Invalidity of Any Single Provision. In case any provision in
this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
(g) Waiver of Jury Trial. The Company and the Underwriters each hereby irrevocably waive any
right they may have to a trial by jury in respect of any claim based upon or arising out of this
Agreement or the transactions contemplated hereby.
(h) Titles and Subtitles. The titles of the sections and subsections of this Agreement are
for convenience and reference only and are not to be considered in construing this Agreement.
(i) Entire Agreement. This Agreement embodies the entire agreement and understanding between
the parties hereto and supersedes all prior agreements and understandings relating to the subject
matter hereof. This Agreement may not be amended or otherwise modified or any provision hereof
waived except by an instrument in writing signed by the Representative and the Company.
30
Please confirm that the foregoing correctly sets forth the agreement among the Company
and the several Underwriters.
Very truly yours, CLINICAL DATA, INC. |
||||
By: | /s/ Xxxxxx X. Xxxxxx | |||
Name: | Xxxxxx X. Xxxxxx | |||
Title: | Executive Vice President, Chief Legal Officer and Secretary |
|||
Confirmed as of the date first above mentioned: BMO CAPITAL MARKETS CORP. Acting on behalf of itself and as the Representative of the several Underwriters named in Schedule I hereof |
||||
By: | /s/ Xxxx X. Xxxxxx | |||
Name: | Xxxx X. Xxxxxx | |||
Title: | Managing Director | |||
31
SCHEDULE I
UNDERWRITERS
Number of Firm Shares | ||||
Underwriters | to be Purchased | |||
BMO Capital Markets Corp. |
1,459,182 | |||
Wedbush Xxxxxx Securities, Inc. |
311,292 | |||
Xxxx Capital Partners, LLC |
175,102 | |||
TOTAL: |
1,945,576 |
SCHEDULE II
PRICING INFORMATION
Price Per Share:
|
$14.30 | |
Offering Size:
|
1,945,576 shares | |
Underwriting Discount:
|
5.75% | |
Closing Date:
|
June 14, 2010 |
SCHEDULE III
ISSUER FREE WRITING PROSPECTUS
Free
Writing Prospectus filed on June 9, 2010 (File No. 333-143883)
EXHIBIT A
CLINICAL DATA, INC.
LOCK-UP AGREEMENT
, 2010
BMO CAPITAL MARKETS CORP.
As Representative of the Several Underwriters
0 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
As Representative of the Several Underwriters
0 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
In consideration of the agreement of the several Underwriters, for which BMO Capital Markets
Corp. intends to act as representative (the “Representative”), to underwrite a proposed public
offering (the “Offering”) of shares of common stock, $0.01 par value per share (the “Stock”), of
Clinical Data, Inc., a Delaware corporation (the “Company”), the undersigned hereby irrevocably
agrees that the undersigned shall not, for a period (the “Lock-Up Period”) beginning on the date of
this letter agreement and ending 90 days after the date of the final Prospectus Supplement for the
Offering, without the prior written consent of the Representative (which consent may be withheld in
its sole discretion), (1) offer to sell, sell, pledge, contract to sell, purchase any option to
sell, grant any option for the purchase of, lend, or otherwise dispose of, or require the Company
to file with the Securities and Exchange Commission a registration statement under the Securities
Act of 1933, as amended, to register, any shares of Stock or any securities convertible into or
exercisable or exchangeable for Stock or warrants or other rights to acquire shares of Stock of
which the undersigned is now, or may in the future become, the beneficial owner (within the meaning
of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other
than pursuant to employee stock option plans or Rule10b5-1 plans existing on the date of the
Prospectus)), or (2) enter into any swap or other derivatives transaction that transfers to
another, in whole or in part, any of the economic benefits or risks of ownership of such shares of
Stock or such other convertible, exercisable or exchangeable securities, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery of Stock or other
securities, in cash or otherwise; except that if (i) during the period that begins on the date that
is 15 calendar days plus three business days before the last day of the Lock-Up Period and ends on
the last day of the Lock-Up Period, the Company issues an earnings release or material news or a
material event relating to the Company occurs, or (ii) prior to the expiration of the Lock-Up
Period, the Company announces that it will release earnings results during the 16-day period
beginning on the last day of the Lock-Up Period, the restrictions imposed by this letter agreement
shall continue to apply until the expiration of the date that is 15 calendar days plus three
business days after the date on which the issuance of the earnings release or the material news or
material event occurs, provided, however, this provision extending the Lock-Up Period will not
apply if, within three days of the termination of the Lock-Up Period, the Company delivers to the
Representative a certificate, signed by the Chief Financial Officer or Chief Executive Officer of
the Company, certifying on behalf of the Company that the Company’s shares of Stock are, as of the
date of delivery of such certificate,
B-1
“actively trading securities,” as defined in Regulation M under the Exchange Act. The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s
transfer agent and registrar against the transfer of shares of Stock or securities convertible into
or exercisable or exchangeable for Stock owned either of record or beneficially by the undersigned
except in compliance with the foregoing restrictions.
The foregoing restrictions shall not apply, however, to (a) transfers of any shares of Stock
as a bona fide gift or pledge, (b) in the case of a natural person, transfers of any shares of
Stock by will or intestate succession or to any trust or partnership for the direct or indirect
benefit of the undersigned or any member of the immediate family of the undersigned, (c) in the
case of a non-natural person, distributions of any shares of Stock to general or limited partners
or stockholders or members of the undersigned, (d) in the case of a non-natural person, transfers
of any shares of Stock (A) in connection with the sale or other bona fide transfer in a single
transaction of all or substantially all of the undersigned’s capital stock, partnership interests,
membership interests or other similar equity interests, as the case may be, or all or substantially
all of the undersigned’s assets, in any such case not undertaken for the purpose of avoiding the
restrictions imposed by this Agreement or (B) to another corporation, partnership, limited
liability company or other business entity so long as the transferee is an affiliate of the
undersigned and such transfer is not for value, (e) the “net” exercise of outstanding options to
purchase Stock in accordance with their terms, or (f) transfers pursuant to a sale or an offer to
purchase 100% of the outstanding Stock, whether pursuant to a merger, tender offer or otherwise, to
a third party or group of third parties; provided that in the case of any transfer or distribution
pursuant to clauses (a), (b), (c) or (d), each donee, pledgee, distributee or transferee shall sign
and deliver a lock-up agreement substantially in the form of this Agreement; and provided, further,
that any Stock acquired upon the net exercise of options described in clause (e) above shall be
subject to the restrictions imposed by this Agreement, and no such net exercise of options shall
involve any disposition of Stock into the public market. For the purposes of this paragraph,
“immediate family” shall mean spouse, domestic partner, lineal descendant (including adopted
children), father, mother, brother or sister of the transferor.
Very truly yours, |
||||
By: | ||||
Print Name: | ||||
B-2
EXHIBIT B
FORM OF OPINION OF COMPANY COUNSEL
EXHIBIT C
FORM OF CHIEF FINANCIAL OFFICER’S CERTIFICATE
I,
C. Xxxx Xxxxxxxxxx, do hereby certify that I am the Chief Financial Officer of Clinical
Data, Inc., a Delaware corporation (the “Company”), and, in my capacity as Chief Financial Officer,
do hereby certify that:
1. I am providing this certificate in connection with the offering (the “Offering”) by the
Company of shares of the Company’s common stock, $0.01 par value (the “Common Stock”) as described
in that certain Registration Statement on Form S-3 (No. 333-143883), including the final prospectus
supplement filed with the Securities and Exchange Commission (the “Commission”) on June 9, 2010
pursuant to Rule 424(b) of the Securities Act (the “Registration Statement”).
2. I am familiar with the accounting, operations and records systems of the Company.
3. I have supervised the compilation of and reviewed the circled information contained on the
attached Exhibit A and, to my knowledge, such information is accurate in all material
respects.
This certificate is being furnished to BMO Capital Markets Corp. as representative of the
several underwriters for the Offering, solely to assist the underwriters in conducting their
investigation of the Company in connection with the Offering. This certificate shall not be used,
quoted or otherwise referred to without the prior written consent of the Company.
C-1